Ascendis Pharma A/S
- ASND
- NASDAQ
- Biotechnology
- Growth Hormone Therapy
- Rare Disease Treatments
$229.95
Today +2.09%Quote Oct 19, 2026, 08:00 PM UTC
−2.86%over the last month
Max drawdown −6.3%From 1-month high −3.2%3 months −9.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
1,189
Founded
2006
Market value
$14.34B
Quote Oct 19
Floor
$227.09
1.2% below price
Resistance
$230.65
0.3% above price
Price vs analyst targets
26 analysts
Lowest target
$269.00Highest target
$344.00
$269.00Highest target
$344.00
- Price $229.95
- Average target $311.17
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 35% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ASNDPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free